Imaging Biomarkers of Lymphatic Dysfunction

Status Recruiting

Clinical Trial Summary

Persons with secondary arm and/or upper quadrant lymphedema following cancer therapies commonly are prescribed complete decongestive therapy as a course of management of their lymphedema. The investigators will perform a repeated-measures cross-over trial to test the hypothesis that mobilization of protein enriched hardened tissue using graded negative pressure therapy in conjunction with complete decongestive therapy (CDT) is more effective to standard CDT alone for secondary lymphedema management.

Clinical Trial Description

The goal of this work is to apply novel, noninvasive magnetic resonance imaging (MRI) methods for visualizing lymphatic circulation dysfunction to test a fundamental hypothesis about secondary lymphedema conservative decongestive therapy. Breast cancer treatment-related lymphedema (BCRL) arises secondary to surgical axillary lymph node (LN) dissection and irritation, and is a chronic and lifelong condition affecting a high 21.4% of patients receiving common breast cancer therapies. Persons with secondary lymphedema following axillary lymph node removal also include undergoing treatment for other cancers, such as melanoma involving the upper body, necessitating the need for axially lymph node removal. Improving lymphedema management represents a major clinical need, and emerging efforts focus on improving quality of life through optimizing post-surgical complex decongestive therapy (CDT), and exploring novel pharmacological and surgical procedures. Here, the investigators will perform a repeated-measures cross-over trial to test the hypothesis that mobilization of protein enriched hardened tissue using graded negative pressure therapy in conjunction with complete decongestive therapy (CDT) is more effective to standard CDT alone for secondary lymphedema management. Both of these conservative physical therapy treatments are commonly employed for treatment of secondary lymphedema. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03760744
Study type	Interventional
Source	Vanderbilt University Medical Center
Contact	Paula M Donahue, DPT
Phone	615-343-0389
Email	paula.m.donahue@vumc.org
Status	Recruiting
Phase	N/A
Start date	January 23, 2019
Completion date	December 15, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03572998` - Lymphatic Function in Patients Who Have Undergone Breast Cancer Treatment	N/A
Active, not recruiting	`NCT02895724` - Hyperbaric Oxygen Therapy to Reduce Lymphedema After Breast Cancer -an Explorative Clinical Trial	Phase 2
Completed	`NCT04393168` - Proof-of-concept Study of LymphMonitor 1.0 to Assess the Lymphatic Vessel Function	Phase 1
Active, not recruiting	`NCT05441943` - Lymphaticovenous Anastomosis as Treatment for Lymphedema	N/A
Active, not recruiting	`NCT03658967` - Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE)	Phase 2
Terminated	`NCT02994771` - A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema	Phase 1
Completed	`NCT04897035` - A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Dayspring Active Wearable Compression Technology for Treating Lower Extremity Lymphedema	N/A
Recruiting	`NCT03578380` - Supermicrosurgery for Breast Cancer Survivors With Lymphedema.	N/A
Completed	`NCT04045860` - Complete Decongestive Therapy on Head and Neck Lymphedema	N/A
Completed	`NCT03634462` - Complete Decongestive Therapy With Negative Pressure for Lipedema and Lymphedema Therapy	N/A
Completed	`NCT03523494` - Feasibility of Lymph Edema-induced Reticulation Subtraction Based on Computerized Tomography
Completed	`NCT01748604` - Physical Therapies in the Decongestive Treatment of Lymphedema	N/A